Cargando…
p16(INK4a), a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV‐Infected Subjects
The goal of this study was to explore the relationships between tenofovir (TFV) and emtricitabine (FTC) disposition and markers of biologic aging, such as the frailty phenotype and p16(INK4a) gene expression. Chronologic age is often explored in population pharmacokinetic (PK) analyses, and can be u...
Autores principales: | Dumond, JB, Collins, JW, Cottrell, ML, Trezza, CR, Prince, HMA, Sykes, C, Torrice, C, White, N, Malone, S, Wang, R, Patterson, KB, Sharpless, NE, Forrest, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321809/ https://www.ncbi.nlm.nih.gov/pubmed/28019088 http://dx.doi.org/10.1002/psp4.12150 |
Ejemplares similares
-
Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV‐Infected Subjects With Aging Biomarkers
por: Dumond, JB, et al.
Publicado: (2016) -
Concentrations of Pro-Inflammatory Cytokines Are Not Associated with Senescence Marker p16(INK4a) or Predictive of Intracellular Emtricitabine/Tenofovir Metabolite and Endogenous Nucleotide Exposures in Adults with HIV Infection
por: Maas, Brian M., et al.
Publicado: (2016) -
Model‐Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV‐Infected Pregnant Women Supports Standard Dosing in the Third Trimester
por: Chen, J, et al.
Publicado: (2016) -
Review of tenofovir-emtricitabine
por: Masho, Saba Woldemichael, et al.
Publicado: (2007) -
Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
por: Sax, Paul E., et al.
Publicado: (2018)